Lb Pharmaceuticals (LBRX) Total Current Liabilities (2024 - 2026)

Lb Pharmaceuticals' Total Current Liabilities history runs 3 years deep, the most recent figure standing at $10.9 million for Q1 2026.

• In Q1 2026, Total Current Liabilities changed N/A year-over-year to $10.9 million; the TTM figure through Mar 2026 stood at $10.9 million (changed N/A YoY), while the FY2025 annual figure was $7.4 million, down 8.23% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $10.9 million, up from $7.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $10.9 million in Q1 2026, with the low at $6.6 million in Q3 2025.
• The 3-year median for Total Current Liabilities is $7.8 million (2024), against an average of $8.3 million.
• Peak annual rise in Total Current Liabilities reached 8.23% in 2025, while the deepest fall reached 8.23% in 2025.
• Lb Pharmaceuticals' Total Current Liabilities stood at $8.1 million in 2024, then slipped by 8.23% to $7.4 million in 2025, then jumped by 46.55% to $10.9 million in 2026.
• Business Quant data shows LBRX's Total Current Liabilities at $10.9 million in Q1 2026, $7.4 million in Q4 2025, and $6.6 million in Q3 2025.